Nymox Pharmaceutical Corporation
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of products for the aging population. Its lead drug candidate is Fexapotide Triflutate (NX-1207) for the treatment of benign prostatic hyperplasia and low-grade localized prostate cancer, as well as hepatocellular carcinoma. The company also offers NicAlert, a test for determining smoking status; and TobacAlert, a test for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment and prevention of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, Bahamas.
Moat, DCF and rating computed by our valuation engine (ported from the original Python model).